Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy

Mol Ther. 2018 Mar 7;26(3):675-677. doi: 10.1016/j.ymthe.2018.02.006. Epub 2018 Feb 21.

Authors

Mario M Soldevilla¹, Fernando Pastor²

Affiliations

¹ Molecular Therapeutics Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.
² Molecular Therapeutics Program, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain. Electronic address: fpasrodri@unav.es.

No abstract available

Publication types

Comment

MeSH terms

Humans
Immunologic Factors*
Immunotherapy*
Lymphoma, B-Cell
Oligonucleotides
STAT3 Transcription Factor
Toll-Like Receptor 9

Substances

Immunologic Factors
Oligonucleotides
STAT3 Transcription Factor
STAT3 protein, human
TLR9 protein, human
Toll-Like Receptor 9